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AbstrAct
Hypoxic environment is critical in colorectal cancer (CRC) development. Most 
studies have mainly focused on hypoxia-inducible factor (HIF)-1α and HIF-2α as the 
major hypoxic transcription factors in CRC development and progression. However, 
the role of HIF-3α in CRC is not clear. Here we found that HIF-3α protein was increased 
in colorectal tumors from both mouse models and human patients. Moreover, 
increased HIF-3α expression was correlated with decreased survival. Overexpression 
of a long isoform of HIF-3α, HIF-3α1, increased cell growth in two CRC cell lines. 
Surprisingly, overexpressed HIF-3α1 was localized to the cytosol and increased 
phosphorylated signal transducer and activator of transcription 3 (p-STAT3). STAT3 
inhibition effectively reduced p-STAT3 levels and cell growth induced by HIF-3α1. 
The activation of p-STAT3 was independent of the transcriptional activity of HIF-3α1.  
However, the inhibition of the upstream regulator Janus kinase (JAK) abolished  
HIF-3α1-induced p-STAT3 and cell growth. Together, these results demonstrated that 
HIF-3α1 promotes CRC cell growth by activation of the JAK-STAT3 signaling pathway 
through non-canonical transcription-independent mechanisms.
IntroductIon
Hypoxia-inducible factors (HIFs) are transcription 
factors that mediate hypoxia signaling, which is crucial 
in many cellular process including cancer development 
and progression. HIF is a heterodimer consisting of a 
hypoxia-inducible alpha subunit (HIF-α) and a 
constitutively expressed beta subunit (HIF-1β, or aryl 
hydrocarbon receptor nuclear translocator [Arnt]) [1]. 
Under normoxic cell conditions, HIF-α is hydroxylated by 
the oxygen-sensitive prolyl hydroxylase domain protein 
(PHD) and recognized by the von Hippel-Lindau tumor 
suppressor protein (VHL) coupled to the E3 ubiquitin 
ligase complex to initiate its degradation [2, 3]. However, 
in a hypoxic environment, the binding of VHL to HIF-α 
is decreased, which results in an accumulation of HIF-α 
and activation of its target gene expression [4]. There 
are three major isomers of HIF-α: HIF-1α, HIF-2α, and 
HIF-3α. While numerous studies have shown that HIF-1α 
and HIF-2α are activated in both physiologic and 
pathologic conditions [5], very little is known about 
HIF-3α.
Unlike HIF-1α and HIF-2α, HIF-3α contains at 
least 10 predicted mRNA variants in humans from the 
utilization of different promoters, different transcription 
initiation sites, and alternative splicing have been 
identified [6]. HIF-1α and HIF-2α share a high homology 
and both have two prolyl sites and two transactivation 
domains (TADs, N-terminal and C-terminal), whereas 
HIF-3α has only one prolyl site and the N-terminal TAD 
[7]. Thus HIF-3α can still be induced by hypoxia [8], 
and certain long isoforms, such as HIF-3α1, can increase 
a distinct set of HIF-α target genes [7, 9]. Both HIF-1α 
and HIF-2α are overexpressed in colorectal cancer (CRC) 
tissues from patients [10, 11]. HIF-1α is required for 
pro-inflammatory regulation and promotes the survival of 
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CRC cell lines under hypoxic condition [12, 13], whereas 
HIF-2α increases genes important in proinflammatory 
response, tumor growth and invasion in mice [14–17]. 
Here, we hypothesize that HIF-3α also promotes the 
development and progression of CRC.
This study demonstrates that HIF-3α is 
overexpressed in both mouse and human colorectal 
tumors, and predicts poor prognosis. Overexpression of 
HIF-3α1 greatly increases colorectal tumor cell growth. 
Interestingly, overexpressed HIF-3α1 is localized to the 
cytosol and can strongly activate the pro-survival signal 
transducer and activator of transcription 3 (STAT3) 
signaling, which is essential for HIF-3α-promoted 
CRC cell growth. Further investigation shows that the 
upstream signal Janus kinase (JAK) is important for 
HIF-3α-promoted STAT3 activation. Together, these 
data uncovered a novel role for HIF-3α in activating the 
JAK-STAT3 signaling cascade to influence the cell 
proliferation and growth of CRC. 
results
HIF-3α is overexpressed in both mouse and 
human colorectal tumors and predicts poor 
prognosis
Previously, we have reported that intestine-specific 
disruption of Vhl (Vhl∆IE) activates HIF signaling, and 
when these mice are crossed to the Apcmin/+ intestinal 
tumor model (Vhl∆IE/Apcmin/+), colorectal tumorigenesis 
is robustly increased compared with littermate control 
mice (VhlF/F/Apcmin/+) [14]. HIF-3α expression was further 
assessed in the normal and tumor tissues of Vhl∆IE/Apcmin/+ 
and VhlF/F/Apcmin/+ mice (Figure 1A). Tumors isolated from 
VhlF/F/Apcmin/+ mice demonstrate an increase in HIF-3α 
expression compared to their adjacent normal tissue. 
Furthermore, the Vhl knockout mouse model (Vhl∆IE/
Apcmin/+) demonstrates an increase in HIF-3α expression 
in both normal and tumor tissue samples. In addition, 
colorectal tumors isolated from patients demonstrated 
an increase in HIF-3α compared to their adjacent normal 
tissue (Figure 1B). These data demonstrate that HIF-3α is 
overexpressed in both mouse and human colorectal tumors. 
Moreover, Kaplan-Meier survival curves were generated 
and stratified using datasets published under the GEO 
accession numbers GSE12945, GSE14333, GSE17538, 
GSE31595, GSE33114, GSE37892, GSE39582, 
and GSE41258. Increased expression of HIF-3α 
in patient specimens predicted worse patient survival 
(Figure 1C). Together, these data suggest that HIF-3α is 
important in colorectal tumor development and cancer 
progression. 
Overexpression of HIF-3α1 in CRC cells 
promotes cell growth
To determine if the increased HIF-3α expression 
contributes to the increase in colorectal tumorigenesis, 
HIF-3α1 was stably overexpressed in two CRC-derived 
cell lines, HT29 and SW480. We chose to overexpress 
HIF-3α1 since it is the longer isoform of human HIF-3α 
and the size of HIF-3α1 was close to the increased HIF-3α 
detected in human CRC tumors by Western blot analysis 
(Figure 1B). In addition, HIF-3α1 has a significantly 
higher activity than the shorter isoforms such as HIF-3α4, 
which has no TAD and thus no activity [9]. By qPCR 
analysis, the HIF-3α mRNA expression was significantly 
increased in the lentiviral HIF-3α1 infected cells compared 
to the lentiviral empty vector (EV) infected cells in both 
HT29 and SW480 cells (Figure 2A). Western blot analysis 
for flag-tagged HIF-3α1 confirmed stable overexpression 
of HIF-3α1 (Figure 2B). Cell growth was assessed and 
the results indicated that the HIF-3α1 overexpressing cells 
exhibited increased growth rate over a 72-hour period 
compared to EV cells (Figure 2C). A colony formation 
assay was performed to confirm these results, and as 
expected, the HIF-3α1 overexpressing cells formed more 
colonies compared to the EV cells (Figure 2D and 2E). 
These results demonstrate that HIF-3α1 overexpression 
may contribute to colorectal tumorigenesis and cancer 
progression. 
HIF-3α1 is localized in the cytosol in  
CRC-derived cell lines and in the colon in  
mouse models
To test whether HIF-3α1 increases cell growth 
through regulating canonical hypoxia response genes, the 
luciferase assay for canonical hypoxia target gene Enolase 
promoter (P2.1) was examined. HIF-3α1 overexpression 
increased the P2.1 luciferase activity, and this was further 
potentiated by HIF-2α (Figure 3A). This suggests that 
HIF-3α1 has a transcriptional activity. To confirm this, 
the cellular distribution of HIF-3α1 was examined. 
Surprisingly, though Flag antibody can recognize both 
nuclear and cytosol flag-tagged HIF-3α1 by Western blot 
analysis, the HIF-3α antibody can only detect HIF-3α1 
in the cytosol fraction in the SW480 cells (Figure 3B). 
Consistent with this in vitro cell line data, the majority 
of HIF-3α protein was found to be located in the cytosol 
fraction from colon extracts of Vhl∆IE mice, whereas the 
majority of HIF-2α protein was in the nuclear fraction 
(Figure 3C). These data suggest that HIF-3α1 increased 
CRC cell growth may not through its transcriptional 
activity.
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Figure 1: HIF-3α is overexpressed in CRC. Western blot analysis for HIF-3α and GAPDH from normal (N) and tumor (T) colorectal 
tissues of (A) 3-month-old VhlF/F/Apcmin/+, and VhlΔIE/Apcmin/+ mice or (b) 14 pairs of human colorectal tumor. (c) Kaplan-Meier survival 
curves of HIF-3α gene in colorectal tumor patients. M.W., molecular weight.
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Figure 2: Overexpression of HIF-3α1 enhances CRC cell and colony growth. (A) qPCR analysis of HIF-3α gene expression, 
(b) Western blot analysis of Flag protein, (c) cell survival determined by MTT assay, (d) colony formation detected by crystal violet 
assay and (e) quantification of colonies formed in flag-tagged HIF-3α1-overexpressing or empty vector (EV) lentivirus infected HT29 and 
SW480 CRC cells. **p < 0.01, ***p < 0.001 compared with EV.
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Overexpression of HIF-3α1 activates STAT3 
signaling
To determine the mechanisms responsible for 
HIF-3α1-enhanced cell growth, Western blot analysis 
was performed for cell cycle, cell survival and apoptosis 
(Figure 4A). A robust increase in phosphorylated signal 
transducer and activator of transcription 3 (p-STAT3) 
was observed in HIF-3α1 overexpressing cells compared 
to EV. STAT3 is a protein known to be important in cell 
proliferation and cell survival in CRC, which is primarily 
activated by interleukin-6 (IL-6) signaling. Consistent with 
an increase in p-STAT3, STAT3 activity was also increased 
in HIF-3α1 overexpressing cell lines, and the activity 
was further enhanced by IL6 stimulation (Figure 4B). 
Furthermore, the gene expression of SOCS3, a known 
target gene of STAT3 signaling, was increased by HIF-3α1 
overexpression (Figure 4C). Together, these data indicate 
that HIF-3α can robustly activate STAT3 signaling.
STAT3 inhibition decreases HIF-3α1-promoted 
cell growth
To confirm the critical role of STAT3 in HIF-
3α1-promoted cell growth, HT29 and SW480 EV and 
HIF-3α1 cells were treated with S3I-201, a STAT3 inhibitor 
(STAT3i). The specificity of this STAT3i is demonstrated 
by the fact that it reduced JAK1 increased STAT3 activity 
(Figure S1A), but not HIF-1α induced P2.1 luciferase 
activity (Figure S1B). Western blot analysis confirmed 
that the STAT3i successfully reduced the HIF-3α1 
increased p-STAT3 levels in both HT29 and SW480 cells 
(Figure 5A). STAT3 inhibition resulted in decreased growth 
in HIF-3α1-overexpressing cells, whereas STAT3i did not 
result in significant decrease in EV cells. (Figure 5B). 
To confirm these results, a colony formation assay was 
performed to assess the relative growth of the cells treated 
with STAT3i compared to the untreated cells (Figure 5C 
and 5D). The results of the colony formation assay showed 
Figure 3: HIF-3α1 can activates hypoxia response gene in CRC cells and is majorly located in the cytosol when 
stabilized. (A) Enolase promoter (P2.1) luciferase assay in HIF-3α1-overexpressing or EV lentivirus infected HT29 and SW480 
CRC cells. Cells were transfected with HIF-2α or EV plasmids. (b) Western blot analysis in the cytosolic and nuclear fraction from 
HIF-3α1-overexpressing or EV lentivirus infected SW480 CRC cells or colorectal tissues of VhlF/F and VhlΔIE mice. *p < 0.05, 
***p < 0.001 compared with EV control cell line. ##p < 0.01, ###p < 0.001 compared with EV control plasmids. M.W., molecular weight.
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Figure 4: Overexpression of HIF-3α1 activates STAT3 signaling in CRC cells. (A) Western blot analysis in whole cell 
extracts from HIF-3α1-overexpressing or EV lentivirus-infected HT29 or SW480 CRC cells. (b) STAT3 activity luciferase assay in 
HIF-3α1-overexpressing or EV lentivirus infected HT29 and SW480 CRC cells. Cells were treated with or without IL6 (10 ng/mL) for 
24 hours. (c) qPCR analysis of SOCS3 gene expression in HIF-3α1-overexpressing or EV lentivirus infected HT29 and SW480 CRC cells. 
*p < 0.05, **p < 0.01, ***p < 0.001 compared with EV control cell line. ##p < 0.01, ###p < 0.001 compared with untreated controls.
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Figure 5: Inhibition of STAT3 decreases HIF-3α1-enhanced CRC cell and colony growth. (A) Western blot analysis of 
p-STAT3 and STAT3 in whole cell extracts, (b) cell survival determined by MTT assay, (c) colony formation detected by crystal violet 
assay and (d) quantification of colonies formed from STAT3 inhibitor (STAT3i) treated or untreated HIF-3α1-overexpressing or EV 
lentivirus-infected HT29 or SW480 CRC cells. *p < 0.05, **p < 0.01, ***p < 0.001 compared with EV control cell line. #p < 0.05, 
##p < 0.01, ###p < 0.001 compared with untreated controls.
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that STAT3i significantly reduced HIF-3α1-enhanced 
colony growth. Together, these data indicate that STAT3 
activation is necessary for HIF-3α1-promoted cell 
proliferation.
HIF-3α-promoted activation of STAT3 is 
independent of its transcriptional activity
To further understand how HIF-3α1 induces STAT3 
activation, mRNA analysis for the STAT3 signaling 
pathways was assessed. Real-time qPCR analysis 
showed that the STAT3 mRNA levels were not changed 
by overexpression of HIF-3α1 (Figure 6A and 6B). 
Furthermore, several genes such as IL6, IL6R and 
GP130 that are important in STAT3 activation were not 
increased by overexpression of HIF-3α1 either. HIF 
transcription factors recently have been shown to have 
non-transcriptional function important in cell cycle and 
cancer progression [18, 19]. Under hypoxia, cells switch 
to selective cap-dependent translation initiation machinery 
for protein synthesis [20]. However this has not been 
shown for HIF-3α1. To understand if transcriptional 
activation by HIF-3α1 was required for the enhanced 
STAT3 activation, cells were treated with Actinomycin D 
(Act D), a transcription inhibitor. Act D time-dependently 
decreased the expression of cyclin D1, which indicates the 
effectiveness of this compound. However, Act D did not 
inhibit the p-STAT3 activation by HIF-3α1 (Figure 6C). 
Furthermore, knocking down Arnt, a cofactor essential 
for the transcriptional activity of all isoforms of HIF-α, 
effectively reduces the protein levels of Arnt to about 
30%–40% compared to scrambled control in both EV and 
HIF-3α overexpressing cell lines, but it did not reduce 
the HIF-3α-increased p-STAT3 level (Figure 6D). These 
results suggest that HIF-3α1 activated p-STAT3 is via 
a non-transcriptional mechanism. Since STAT3 can be 
activated by several growth factors such as EGF [21], to 
exclude the effects of serum containing factors, cells were 
incubated in serum-free medium (SFM) (Figure 6E). The 
p-STAT3 level was slightly decreased but still significantly 
increased compared to EV cells. To further evaluate if 
paracrine-signaling factors led to an increase in p-STAT3 
by HIF-3α1, EV cells were treated with conditioned media 
from HIF-3α1 overexpressing cells. HIF-3α1 conditioned 
media did not activate p-STAT3 in EV cells (Figure 6F), 
suggesting that the activation of STAT3 is a cell intrinsic 
mechanism.
HIF-3α-activated STAT3 requires JAK
JAK is a known upstream kinase that phosphorylates 
STAT3, which allows STAT3 to translocate into the 
nucleus and initiate transcription [22–24]. To determine 
whether HIF-3α1 is capable of binding with JAK and 
triggering the JAK-STAT signaling cascade, cells were 
treated with Ruxolitinib, a JAK1/2 inhibitor (JAKi). 
Western Blot analysis showed that JAK inhibition 
completely abolished the HIF-3α1-increased STAT3 
activation (Figure 7A). MTT assay indicated that JAKi 
abrogated HIF-3α1-increased growth (Figure 7B). Colony 
formation assay further confirmed that JAKi reduced 
colony growth of HIF-3α-overexpressing and EV cells in 
a dose-dependent manner (Figure 7C and 7D). Together, 
these data indicate that HIF-3α1 increases CRC cell 
proliferation and survival by activation of the JAK-STAT 
signaling pathway 
dIscussIon
Hypoxia is a hallmark of solid tumors. Through 
increasing the stability of HIF-α, hypoxia can activate the 
expression of numerous genes involved in cell metabolism, 
cell survival, cell proliferation and cell apoptosis. In 
the intestine, activation of HIF-1α does not increase 
tumorigenesis in mice [25], whereas HIF-2α promotes 
the development of CRC [14]. Here, we demonstrate that 
HIF-3α1, also promotes CRC cell growth. Interestingly, 
the mechanism was not through transcriptional regulation, 
but by activation of the JAK-STAT3 signaling.
The JAK-STAT3 signaling is aberrantly activated in 
the CRC tissues and is critical in promoting carcinogenesis 
[26, 27]. Phosphorylation of STAT3 is positively correlated 
with the tumor invasion of colorectal adenocarcinoma in 
human [28]. Excess activation of STAT3 in enterocytes 
promotes, whereas ablation of STAT3 reduces tumor cell 
proliferation through G1 and G2/M cell cycle progression 
in mouse models of colitis-associated CRC [29]. STAT3 
is activated by many growth factors through their receptor 
tyrosine kinase activity or cytokines such as IL-6 through 
JAK family kinases. Pharmacological inhibition of 
JAK activity inhibits progression of gastrointestinal 
tumors in mice [27]. The current study demonstrates 
that JAK-STAT3 signaling is also activated by HIF-3α1, 
which provides a novel insight in JAK-STAT3 activity 
modulation.
HIF-3α is originally identified to have a repressive 
activity since its short isoforms such as HIF-3α4 inhibit 
the action of HIF-1α and HIF-2α [30]. However, a recent 
report shows that HIF-3α1 also has a strong transactivation 
activity [9]. We also found that HIF-3α1 can potentiate the 
activity of HIF-2α in CRC cells. Interestingly, HIF-3α1 
can also stimulate cellular JAK-STAT3 activity through a 
transcription-independent mechanism. There are at least 
three major isoforms of JAK: JAK1, JAK2 and JAK3. 
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Western blot analysis failed to detect the activation of 
phospho-JAK2 in HIF-3α1 overexpression cells, further 
studies are still needed to understand which isoform is 
responsible for HIF-3α-increased STAT3 activation and to 
dissect the precise mechanisms for how HIF-3α binds with 
JAK. Also, it is necessary to validate our results in vivo 
using mouse models of colorectal tumors.
In conclusion, our findings demonstrate that HIF-3α 
activates JAK-STAT3 signaling pathway to facilitate CRC 
cell growth. Thus, together with our previous report about 
Figure 6: HIF-3α1-promoted activation of STAT3 is not through increased transcription. qPCR analysis in HIF-3α1-
overexpressing or EV lentivirus infected (A) HT29 and (b) SW480 CRC cells. Western blot analysis of p-STAT3 and STAT3 in whole 
cell extracts from (c) transcription inhibitor Actinomycin D (ActD), (d) siArnt, siScr treated or untreated control, (e) serum free medium 
(SFM) treated or untreated, or (F) conditional medium collected from cell culture treated HIF-3α1-overexpressing or EV lentivirus-infected 
HT29 or SW480 CRC cells. *p < 0.05, **p < 0.01, ***p < 0.001 compared with EV control cell line. NS, not significant.
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Figure 7: HIF-3α-promoted activation of STAT3 requires JAK signaling. (A) Western blot analysis of p-STAT3 and STAT3 
in whole cell extracts, (b) cell survival determined by MTT assay, (c) colony formation detected by crystal violet assay and quantification 
of colonies formed from JAK1/2 inhibitor (JAKi) treated or untreated HIF3A1-overexpressing or EV lentivirus-infected HT29 or SW480 
CRC cells. *p < 0.05, **p < 0.01, ***p < 0.001 compared with EV control cell line. #p < 0.05, ##p < 0.01, ###p < 0.001 compared with 
untreated controls.
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the tumor-promoting role of HIF-2α in CRC, inhibiting 
hypoxia signaling may provide a promising strategy for 
the prevention and treatment of CRC.
MATeRIAlS And MeTHOdS
Animals
VhlF/F, VhlΔIE, VhlF/F/Apcmin/+ and VhlΔIE/Apcmin mice 
were described previously [15]. All mice were on a 129S6/
SvEv background and maintained in standard cages in a 
light and temperature-controlled room and were allowed 
standard chow and water ad libitum. All animal studies 
were carried out in accordance with the Institute of 
Laboratory Animal Resources guidelines and approved by 
the University Committee on the Use and Care of Animals 
at the University of Michigan.
Human colorectal tumor tissues
Human colorectal tumor and adjacent normal tissues 
were obtained from individuals undergoing colorectal 
tumor removal surgery. The Institutional Review Board 
of the University of Michigan approved the use of these 
materials.
Western blot analysis
Whole-cell or nuclear extracts were isolated as 
previously described [14]. Proteins were separated and 
transferred to nitrocellulose membranes using standard 
methods. Antibodies against HIF-3α (Abcam Inc., 
Cambridge, MA), Flag (Sigma, St. Louis, MO), HIF-2α 
(Novus Biologicals, Littleton, CO), Histone H3, p-STAT3, 
STAT3, P21, P53 (Cell Signaling Technology, Danvers, 
MA), Cyclin D1, Cyclin B1, CDK1, CDK2, Arnt and 
GAPDH (Santa Cruz Biotechnology, Dallas, TX) were used.
Meta-analysis of CRC samples
CRC gene expression datasets with survival 
were identified in GEO using the search keywords 
“colorectal”, “cancer”, and “microarray” (http://www.
ncbi.nlm.nih.gov/geo/). Only publications providing 
raw data, clinical survival information, and containing 
at least 30 patients were included. The gene chips were 
MAS 5.0 normalized in the R statistical environment 
(http://www.R-project.org) using the Bioconductor 
package Affy (http://www.bioconductor.org). Survival 
analysis using Cox proportional hazards regression was 
performed as described previously [31]. The most reliable 
probe sets for each gene were selected using Jetset. 
All percentiles between lower and upper quartiles are 
computed, and the best performing threshold is used as 
a cutoff. The values lower than the cutoff are designated 
as “low”, whereas the values higher than cutoff are 
designated as “high”.
Cell culture
HT29 and SW480 CRC cells were obtained from 
ATCC and maintained at 37°C in 5% CO2 and 21% O2. 
Cells were cultured in Dulbecco’s modified eagle medium 
(DMEM) supplemented with 10% Fetal Bovine Serum 
(FBS) and 1% antibiotic/antimycotic. Early-passage 
(P10) stable HIF3A1-expressing and parental HT29 or 
SW480 cells were generated by lentiviral infection of 
pLentilox-puro-HIF3A1 or pLentilox-puro empty vector 
(EV) and selected by 2-μg/mL puromycin. The cells were 
maintained in growth media as described above albeit 
supplemented with 1 μg/mL of puromycin. For condition 
medium collection, fresh FBS-free culture medium 
DMEM was added to the 10 cm plates with cells and 
incubated overnight, the next day the culture medium was 
collected and centrifuged at full speed for 10 min to get 
rid of floating cell debris. One mL of the supernatant was 
added to the cells plated in 6-well plates the day before as 
indicated.
Quantitative real-time RT-PCR (qPCR)
RNA was isolated from frozen tissue using Isol-RNA 
lysis reagent (3 Prime, Gaithersburg, MD) and quantitated 
using the NanoDrop 2000 (NanoDrop products, 
Wilmington, DE). RNA with a purity (260/280 ratio) of 
approximately 2.0 was reverse-transcribed using M-MLV 
Reverse Transcriptase (Fisher Scientific, Waltham, MD). 
mRNA expression was measured by Real Time RT-PCR 
using SYBR green (Life Technologies, Carlsbad, CA) 
(primers are listed in Supplementary Table 1). Ct values 
were normalized to β-actin and expressed as fold 
difference from controls.
MTT assay
Cells were plated at a concentration of 5 × 104 
cells/mL in a 24-well plate. After 24-, 48-, or 72-hr 
culture in the presence or absence of STAT3 inhibitor 
(STAT3i, 100 μM), JAK1/2 inhibitor (JAKi, 3 or 15 μM), 
125 μL 5 mg/mL Thiazolyl Blue Tetrazolium Bromide 
(MTT, Sigma, MO) was added to each well and incubated 
for 30 min. Dimethyl sulfoxide was added and absorbance 
was measured at 570 nm.
Colony formation assay
Cells were plated at a concentration of 500 cells/
mL in a 6-well plate. Cells were treated with or without 
STAT3i (100 μM) or JAKi (3 or 15 μM) every two days 
for 10 days. Formed colonies were fixed with 10% neutral 
buffered formalin solution and stained with 0.01% crystal 
violet for 30 minutes. Excess crystal violet was washed 
with Millipore H2O for 3 times and allowed to dry. Digital 
images of the colonies were obtained. Methanol was added 
to dissolve the crystal violet and absorbance at 540 nm 
was measured. 
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luciferase assay
Cells were seeded into a 24-well plate at a cell 
density of 5 × 104 cells per well. Enolase promoter 
luciferase reporter constructs P2.1 or STAT3 activity 
reporter luciferase construct pGL4.47 [luc2P/SIE/Hygro] 
was co-transfected with HIF-1α, HIF-2α, JAK1 or empty 
vector  (EV) into cells with polyethylenimine (PEI; 
Polysciences Inc., Warrington, PA). Cells were treated 
with 10 ng/mL IL6 or 100 μM STAT3i at 24 hours after 
transfection as indicated. Cells were lysed in reporter lysis 
buffer (Promega, Madison, WI), and firefly luciferase 
activity was measured and normalized to β-galactosidase 
(β-gal) activity 48 hours after transfection.
siRnA knockdown assay
Cells were seeded into a 12-well plate at a cell 
density of 5 × 104 cells per well. Lipofectamine 2000 (Life 
Technologies, Carlsbad, CA) was used for transfection of 
50 nM Arnt siRNA (siArnt) or scrambled siRNA (siScr, GE 
Dharmacon, Lafayette, CO). Cells were collected at 
48 hours after transfection for Western blot analysis as 
described above.
Statistical analysis
Results are expressed as mean ± S.D. Western blot 
analysis were quantified with Image J. p values were 
calculated by independent t-test and two-way ANOVA. 
p < 0.05 was considered significant.
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